Antiangiogenic Targeting Liposomes Increase Therapeutic Efficacy for Solid Tumors

Chang, De-Kuan; Chiu, Chien-Yu; Kuo, Szu-Yao; Lin, Wei-Chuan; Lo, Albert; Wang, Yi Ping; Li, Pi-Chun; Wu, Han-Chung

doi:10.1074/jbc.m900280200

Cited by 97 publications

(78 citation statements)

References 34 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1][2][3] Tumor angiogenesis plays an important role in tumor development, and therefore is also an important sector considered in the treatment of tumors. [4][5][6][7] Different from normal tissues, the vasculatures of tumors show specific overexpressions of cytokines, and therefore can be used as targets for tumor treatment, 8,9 and tumor vasculatures, which are the transport channel of nutrition for the fast proliferating tumor cells, are appropriate therapeutic targets. 4 The disruption of tumor vasculatures can lead to the necrosis of tumors.…”

Section: Introductionmentioning

confidence: 99%

Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor

Li¹,

Wu²,

Pan³

et al. 2015

IJN

View full text Add to dashboard Cite

To overcome the drawback of drug non-selectivity in traditional chemotherapy, the construction of multifunctional targeting drug delivery systems is one of the most effective and prevailing approaches. The intratumoral anti-angiogenesis and the tumor cell-killing are two basic approaches in fighting tumors. Herein we report a novel tumor vascular-targeting multidrug delivery system using mesoporous silica nanoparticles as carrier to co-load an antiangiogenic agent (combretastatin A4) and a chemotherapeutic drug (doxorubicin) and conjugate with targeting molecules (iRGD peptide) for combined anti-angiogenesis and chemotherapy. Such a dual-loaded drug delivery system is capable of delivering the two agents at tumor vasculature and then within tumors through a differentiated drug release strategy, which consequently results in greatly improved antitumor efficacy at a very low doxorubicin dose of 1.5 mg/kg. The fast release of the antiangiogenic agent at tumor vasculatures led to the disruption of vascular structure and had a synergetic effect with the chemotherapeutic drug slowly released in the following delivery of chemotherapeutic drug into tumors.

show abstract

Section: Introductionmentioning

confidence: 99%

Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor

Li¹,

Wu²,

Pan³

et al. 2015

IJN

View full text Add to dashboard Cite

show abstract

“…These novel agents target the endothelium or vasculature of the tumors which make these agents quite distinct from the cytotoxic drugs conventionally used in the treatment of solid tumors. Recently, Chang et al showed that anti-angiogenic targeting liposomes increase therapeutic efficacy of solid tumors and anti-angiogenic ligand-targeted therapy is highly beneficial over conventional anticancer drug therapy (7).…”

Section: Introductionmentioning

confidence: 99%

Angiogenesis: An update and potential drug approaches (Review)

Abdelrahim¹

2009

Int J Oncol

View full text Add to dashboard Cite

Abstract. The therapeutic potential of targeting tumor endothelium and vascular supply is now widely recognized to treat different diseases. One such disease is cancer; where endothelial cells are actively proliferating to support the tumor growth. Solid tumors cannot grow beyond the size of a few millimeters without inducing the proliferation of endothelium and formation of new blood vessels. Hence it is crucial to search for new agents that selectively block tumor blood supply. These include anti-angiogenic molecules, vascular disrupting agents or endothelial disrupting agents. The antiangiogenic molecules such as monoclonal antibodies and tyrosine kinase inhibitors disrupt endothelial cell survival mechanisms and new blood vessel formation, and vascular disrupting agents for instance ligand-directed and small molecules can be used to disrupt the already existing abnormal vasculature that support tumors by targeting their dysmorphic endothelial cells. The recent advances in this area of research have identified a variety of investigational agents which are currently in clinical development at various stages and some of these candidates are already approved in cancer treatment. This report will review some of the recent developments and most significant advances in this field and outline future challenges and directions.

show abstract

“…In the case of tumors, which share the process of neoangiogenesis with arthritis, peptides binding to tumor vasculature have been identified and exploited for suppression of tumor growth in model systems (15,(24)(25)(26)(27). For example, a peptide coupled to the anticancer drug doxorubicin was found to be a more efficacious anticancer agent compared with the drug alone when tested against human breast cancer tissue implanted as a xenograft in nude mice (15).…”

Section: Discussionmentioning

confidence: 99%

Peptides targeting inflamed synovial vasculature attenuate autoimmune arthritis

Yang

Rajesh²,

Ruoslahti³

et al. 2011

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Autoimmune diseases, such as rheumatoid arthritis, frequently target one major tissue/organ despite the systemic nature of the immune response. This is particularly perplexing in the case of ubiquitously distributed antigens invoked in arthritis induction. We reasoned that selective targeting of the synovial joints in autoimmune arthritis might be due in part to the unique attributes of the joint vasculature. We examined this proposition using the adjuvantinduced arthritis model of human rheumatoid arthritis, and profiled the synovial vasculature using ex vivo and in vivo screening of a defined phage peptide-display library. We identified phage that preferentially homed to the inflamed joints. The corresponding synthetic peptides showed binding to the joint-derived endothelial cells, as well as specificity in inhibiting binding of the respective phage to the synovial vasculature. Intriguingly, the treatment of arthritic rats with one such peptide resulted in efficient inhibition of the progression of arthritis. The suppression of arthritis was attributable in part to the peptide-induced reduction of T-cell trafficking into the joints and the inhibition of angiogenesis. This peptide differed in sequence, in receptor binding specificity, and in angiogenesis/inflammation-related cell signaling from the previously characterized arginine-glycine-aspartic acid-containing peptide. Thus, our study reveals joint-homing peptides that can be further exploited for the selective delivery of antiarthritic agents into the inflamed joints to enhance their efficacy while reducing systemic toxicity, and also for examining intricacies of the pathogenesis of arthritis. This approach can be customized for application to other organ-specific autoimmune diseases as well.animal model | leukocyte trafficking | phage display | targeted delivery | vascular endothelial markers

show abstract

Antiangiogenic Targeting Liposomes Increase Therapeutic Efficacy for Solid Tumors

Cited by 97 publications

References 34 publications

Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor

Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor

Angiogenesis: An update and potential drug approaches (Review)

Peptides targeting inflamed synovial vasculature attenuate autoimmune arthritis

Contact Info

Product

Resources

About